Influence of vitamin D on clinical-pathogenetic curriculum of multiple sclerosis

Objective. To investigate the probable effect on the frequency of exacerbations and dynamics of neurological deficits in patients with multiple sclerosis in the use of officinal preparations of vitamin D. Material and methods. 158 patients with relapsing-remitting multiple sclerosis (MS) were assessed. Patients received 4,000 IU/day of Aquadetrim®Vitaminum D3 in late fall and winter and 500-1500 IU/day in spring and summer, as monotherapy (n=32) or with disease modifying drugs (interferon beta or glatiramer acetate) (n=29). 22 patients received disease-modifying drugs only, while 75 patients with MS remained untreated (control). Results. Reduced relapse rates were found in 21.2% of patients with multiple sclerosis in combination with cholecalciferol (vitamin D3) with interferon beta (or glatiramer acetate) (CS: 0.38, CI: [0.146-1.006]) in the study groups. With independent application of officinal preparations of vitamin D and in combination with interferon-beta (or glatiramer acetate), there were no significant differences in changes in functional systems on the EDSS scale between the study groups. Conclusion. Addition of immunomodulatory therapy with the preparation of cholecalciferol (vitamin D3) in patients with multiple sclerosis was associated with a decrease in the proportion of patients who had exacerbations by 2.6 times.